{
}
UBS has maintained a 'Neutral' rating for GSK, setting a target price of 1600 pence. Analyst Jo Walton made adjustments primarily related to currency after a quarterly report conference call, noting that effective cost control has positively impacted sales at the earnings level.
CureVac (CVAC) has seen its price target reduced from $13 to $12 by UBS analyst Eliana Merle, who maintains a Buy recommendation, citing the company's mRNA platform and oncology pipeline as underappreciated. Analysts project an average target price of $6.32, indicating a potential upside of 76.41% from the current price of $3.59. The company reported a strong cash position of EUR481.7 million at the end of 2024 and achieved significant milestones, including a licensing agreement with GSK valued at up to EUR1.45 billion.
A range of companies reported mixed financial results, with hotel group Dalata seeing a 3% share rise amid confidence in Irish properties, while competitor PPHE Hotels faced a 4% drop in shares due to declining revenue per available room. GlobalData's shares surged over 10% after a rating upgrade, while Videndum's successful share placement raised £8mn, signaling recovery potential despite ongoing losses. Aberdeen experienced £5.2bn in outflows, yet its retail platform attracted £1.6bn in inflows, highlighting contrasting performance within the firm.
GSK is well positioned to handle potential tariffs after surpassing market forecasts. The company has established partnerships with 728 vendors, indicating a robust network that supports its operations and strategic initiatives. Microsoft and third-party vendors utilize cookies for service enhancement and personalized content delivery.
The FTSE 100 continued its upward trend, buoyed by strong corporate earnings, particularly from Barclays, which reported a 19% rise in profit before tax. Despite concerns over US tariffs and weak Chinese manufacturing data impacting natural resources stocks, the index remains over 10% higher than its recent lows. GSK and Taylor Wimpey also posted positive results, contributing to investor optimism.
GSK reported a 5% rise in core operating profit to £2.5 billion and remains confident in achieving 2025 growth targets despite potential tariff impacts, highlighting strong performance in Specialty Medicines and R&D advancements. Barclays also exceeded expectations with a 19% increase in pre-tax profit to £2.7 billion, bolstered by a 16% rise in investment banking income and a 14% increase in UK income, as it aims to meet its 2025/26 financial targets. The FTSE 100 is poised for a steady start, nearing its record close, while oil prices continue to decline.
Mixed updates are anticipated in the investment sector, with Microsoft earnings drawing attention amid Wall Street's cautious optimism. Meta is expected to report strong revenue growth, while investors will focus on advertising trends and regulatory challenges. House prices fell 0.6% in April, contrary to expectations, as the market adjusts post-stamp duty changes. Meanwhile, Donald Trump's trade deal priorities have shifted, impacting UK negotiations, although market sentiment improved with news of eased auto tariffs.
The upcoming week will see significant corporate earnings reports from major UK firms like AstraZeneca, HSBC, and Shell, alongside tech giants such as Apple and Microsoft. Key economic data, including US non-farm payrolls and various PMIs, will also be released, influencing market sentiment. Investors are particularly focused on the impact of US tariffs and global economic conditions on these companies' performances.
Barclays maintains its equal weight rating on GSK, citing confidence in the company's Q1 earnings and strategic plans despite challenges in vaccine trials. With projected turnover of £7.55 billion and core EPS of £0.423, GSK's strong performance in specialty and general medicines, along with the upcoming relaunch of Blenrep, positions it favorably in a volatile market. Investors should monitor GSK's adaptability amid evolving healthcare policies and market conditions.
Apple enhances AirPods Max with lossless audio and AI leadership changes, while Tesla faces regulatory hurdles in China and legal issues in the US. Ford is under investigation for gear shifts in F-150 trucks, and Bank of America appoints a new head for India. In Europe, SAP surpasses Novo Nordisk in market value, and Bayer's stock drops after a significant jury verdict. BYD reports a substantial profit increase, and Toyota delays its battery factory project while starting a recycling facility.
GSK plc
Companies
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
ubs maintains neutral rating for gsk with target price of 1600 pence
07:51 01.05.2025
CureVac price target lowered by UBS amid strong financial and regulatory progress
16:02 30.04.2025
diverse market updates hotel openings share fluctuations and financial challenges
British Pound Sterling
Euro
United States Dollar
Aberdeen Group Plc
GSK plc
Melrose Industries PLC
GlobalData Plc
Aston Martin Lagonda Global Hol
Genus plc
IG Design Group plc
Glencore plc
VIDENDUM PLC
Barclays PLC
ESP
USA
Gary Nagle
Adrian Hallmark
John Hennessy
Peter Dilnot
C. S. Venkatakrishnan
Show more
12:10 30.04.2025
GSK demonstrates strong performance amid potential tariff challenges
10:21 30.04.2025
FTSE 100 rises on strong Barclays earnings despite global economic concerns
British Pound Sterling
GSK plc
Barclays PLC
Taylor Wimpey plc
GBR
Susannah Streeter
Matt Britzman
Mark Crouch
Show more
09:48 30.04.2025
Barclays and GSK report strong profits amid tariff concerns and market stability
08:10 30.04.2025
mixed earnings outlook as major companies prepare to report results
British Pound Sterling
Euro
United States Dollar
GSK plc
Barclays PLC
GBR
Robert Gardner
Donald Trump
Show more
07:00 30.04.2025
uk corporate earnings week ahead featuring major banks and tech giants
British Pound Sterling
Euro
United States Dollar
Meta Platforms, Inc.
AstraZeneca PLC
Shell plc
Lloyds Banking Group plc
GSK plc
BP p.l.c.
London Stock Exchange Group plc
Coca-Cola Europacific Partners
Microsoft Corporation
NatWest Group plc
Standard Chartered PLC
Apple Inc.
Whitbread plc
Barclays PLC
GBR
Elon Musk
Donald Trump
Robert F. Kennedy Jr.
Joe Biden
Show more
12:00 25.04.2025
barclays maintains gsk rating amid vaccine challenges and positive earnings outlook
09:00 03.04.2025
global market updates apple tesla ford bank of america and byd news
Morgan Stanley
Roper Technologies, Inc.
James Hardie Industries plc
Toyota Motor Corp
Apple Inc.
Tesla, Inc.
LVMH
Bank of America Corporation
Iren SpA
Azek Co. Inc. R
SAP SE
Dun & Bradstreet Holdings Inc
DBS Group Holdings Ltd
GSK plc
Clearlake Capital Group LP
Elliott Investment Management LP
DEU
FRA
ITA
GBR
USA
CHN
JPN
SGP
Vikram Sahu
Jack McCollough
Tan Su Shan
Lazaro Hernandez
Show more
16:15 24.03.2025
Trending
Subcategory
Corporate News
Industry Trends
Cryptocurrency Trends
Venture Capital Investments
Emerging Startups
Funding Rounds & Investments
Retail and Consumer Goods
Crypto Adoption and Integration
Fintech Startups
AI Innovations
Startups & Entrepreneurship
AI Applications
Economic Indicators
Crypto Policies and Governance
Product Launches
Workplace Trends
Central Banks and Digital Currencies
IPOs of Tech Companies
Market Analysis and Predictions
Real Estate Investments
Countries:
Companies:
Apple Inc.
Nvidia Corporation
DEUTSCHE BANK AG
EVOLUTION JAPAN Securities Co. Ltd.
Alphabet Inc.
Marvell Technology Inc.
Playtika Holding Corp.
Colugo Systems Ltd.
Gemini Trust Company LLC
Circle Internet Financial Inc.
Citigroup Inc.
Bank of America Corporation
Sony Corporation
Zero Networks Ltd.
Ecom Express Ltd.
Minebea Mitsumi Inc.
VOLKSWAGEN AG
Currencies:
People: